Company news

Share this article:
Johnson & Johnson has announced plans to acquire Omrix Biorpharmaceuticals for $438 million. Omrix is expected to operate as a stand-alone entity reporting through J&J-subsidiary Ethicon. Ethicon currently holds exclusive distribution rights for Omrix's Evithrom and Evicel, two biologic-based hemostats.
 
Roche boosted its presence in the Alzheimer's sector with a merger agreement with Memory Pharmaceuticals. Under terms of the agreement, Roche will acquire Memory in a deal worth $50 million. Montvale, NJ-based Memory develops drugs for the treatment of central nervous system disorders such as Alzheimer's disease and schizophrenia. Memory and Roche already have an R&D partnership including a Phase II trial for Alzheimer's and schizophrenia and a Phase I trial for Alzheimer's. Basel, Switzerland-based Roche, which already has a major stake in the Alzheimer's pipeline, expects Memory's work to be fully integrated into Roche's R&D portfolio including the future development of its promising nicotinic alpha-7 agonists. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.